48 related articles for article (PubMed ID: 10803497)
21. Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1.
Lu Y; Xiao Y; Ding J; Dierich M; Chen YH
Int Arch Allergy Immunol; 2000 Jan; 121(1):80-4. PubMed ID: 10686512
[TBL] [Abstract][Full Text] [Related]
22. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein.
Lu Y; Xiao Y; Ding J; Dierich MP; Chen YH
Scand J Immunol; 2000 May; 51(5):497-501. PubMed ID: 10792842
[TBL] [Abstract][Full Text] [Related]
23. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
Tian H; Xiao Y; Qin L; Chen YH
Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398
[TBL] [Abstract][Full Text] [Related]
24. Candidate multi-epitope vaccines in aluminium adjuvant induce high levels of antibodies with predefined multi-epitope specificity against HIV-1.
Ding J; Lu Y; Chen Y
FEMS Immunol Med Microbiol; 2000 Oct; 29(2):123-7. PubMed ID: 11024351
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and specificity of the candidate multi-epitope-vaccines against HIV-1.
Lu Y; Ding J; Chen YH
Immunopharmacol Immunotoxicol; 2001 Nov; 23(4):487-94. PubMed ID: 11792008
[TBL] [Abstract][Full Text] [Related]
26. Induction of high levels of epitope-specific antibodies by epitope/peptide candidate vaccines against human immunodeficiency virus type-1 (HIV-1).
Yu T; Bai Y; Dierich MP; Chen YH
Microbiol Immunol; 2000; 44(2):105-10. PubMed ID: 10803497
[TBL] [Abstract][Full Text] [Related]
27. Roles of HIV-1 Env variable regions in viral neutralization and vaccine development.
Pinter A
Curr HIV Res; 2007 Nov; 5(6):542-53. PubMed ID: 18045110
[TBL] [Abstract][Full Text] [Related]
28. Back to the future: covalent epitope-based HIV vaccine development.
Paul S; Planque S; Nishiyama Y; Escobar M; Hanson C
Expert Rev Vaccines; 2010 Sep; 9(9):1027-43. PubMed ID: 20822346
[TBL] [Abstract][Full Text] [Related]
29. Glycosylation of HIV-1 gp120 V3 loop: towards the rational design of a synthetic carbohydrate vaccine.
Sirois S; Touaibia M; Chou KC; Roy R
Curr Med Chem; 2007; 14(30):3232-42. PubMed ID: 18220757
[TBL] [Abstract][Full Text] [Related]
30. The implications of antigenic diversity for vaccine development.
Zolla-Pazner S; Gomy MK; Nyambi PN
Immunol Lett; 1999 Mar; 66(1-3):159-64. PubMed ID: 10203049
[TBL] [Abstract][Full Text] [Related]
31. Epitope-vaccine as a new strategy against HIV-1 mutation.
Xiao Y; Lu Y; Chen YH
Immunol Lett; 2001 May; 77(1):3-6. PubMed ID: 11348663
[TBL] [Abstract][Full Text] [Related]
32. Turning a corner on HIV neutralization?
Nunberg JH; Follis KE; Trahey M; LaCasse RA
Microbes Infect; 2000 Feb; 2(2):213-21. PubMed ID: 10742693
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 DNA vaccines.
Fomsgaard A
Immunol Lett; 1999 Jan; 65(1-2):127-31. PubMed ID: 10065638
[TBL] [Abstract][Full Text] [Related]
34. V3: HIV's switch-hitter.
Hartley O; Klasse PJ; Sattentau QJ; Moore JP
AIDS Res Hum Retroviruses; 2005 Feb; 21(2):171-89. PubMed ID: 15725757
[TBL] [Abstract][Full Text] [Related]
35. HIV vaccine candidates.
Wu TT; Johnson G
Drugs Today (Barc); 2004 Nov; 40(11):949-55. PubMed ID: 15645007
[TBL] [Abstract][Full Text] [Related]
36. HIV-neutralizing antibodies: epitope identification and significance for future vaccine.
Robert-Guroff M
Int Rev Immunol; 1990; 7(1):15-30. PubMed ID: 1722498
[No Abstract] [Full Text] [Related]
37. Subunit protein vaccines: theoretical and practical considerations for HIV-1.
Cho MW
Curr Mol Med; 2003 May; 3(3):243-63. PubMed ID: 12699361
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 vaccine candidate evaluation in non-human primates.
Lu Y
Crit Rev Oncog; 1997; 8(2-3):273-91. PubMed ID: 9570296
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
